Diagnostic value of MHC class I staining in idiopathic inflammatory myopathies

J van der Pas, G J D Hengstman, H J ter Laak, G F Borm, B G M van Engelen

Background: Identification of mononuclear cellular infiltrates in skeletal muscle tissue is the histological cornerstone of the diagnosis of idiopathic inflammatory myopathy (IIM). However, these infiltrates are not always present.

Objective: To determine whether MHC class I antigen expression on the sarcolemma, which is absent in normal muscle tissue, is upregulated in IIM and could serve as an additional diagnostic test.

Methods: Expression of MHC class I antigens was studied in 224 muscle samples of 61 adult patients with IIM (9 dermatomyositis, 23 polymyositis, 29 inclusion body myositis) and 163 controls (normal subjects and patients with various neuromuscular disorders) in a prospective blinded manner.

Results: The sensitivity of the test for diagnosing IIM was 78% (95% confidence interval (CI), 66% to 88%), with a specificity of 95% (91% to 98%). The sensitivity before the start of immunosuppressive treatment was 89% (76% to 96%). The sensitivity was not changed by including all patients who had been on immunosuppressive treatment for less than four weeks before muscle biopsy (sensitivity 90% (79% to 97%)). False positive results were found in only seven controls (4%), six of whom had a muscular dystrophy.

Conclusions: Detection of sarcolemmal MHC class I is a valid test for IIM. It is not affected by the short term use of immunosuppressive agents (less than four weeks) and it should be incorporated in the histological evaluation when the diagnosis of IIM is under consideration or needs to be excluded.
capillaries and sarcolemma positive for MHC class I antigen (fig 1).

To evaluate the reproducibility of this diagnostic test, intraobserver and interobserver studies were done. The first 50 samples were scored twice by the same investigator (JvdP) and subsequently by an experienced neurobiologist (HJtL). Both the intraobserver and interobserver results were very favourable: intraobserver reproducibility was 92% and interobserver reproducibility, 90%.

To determine the diagnostic value of the test, estimates and 95% confidence intervals (CI) for the sensitivity and specificity were calculated.

After completion of the analysis, data were compared with the clinical data (particularly the type and duration of immunosuppressive treatment) and other histological data.

RESULTS

Of the 224 stained muscle samples, 16 (7%) were of insufficient quality. The remaining 208 samples were used for MHC class I analysis (fig 2). A diffuse pattern of staining was observed in all samples showing positive staining of the sarcolemma. Expression of MHC class I was found in 67% of muscle biopsies from patients with dermatomyositis, in 61% with polymyositis, and in 96% with inclusion body myositis. No expression was detected in any of the patients with congenital or metabolic myopathies or neurogenic disorders, or in the healthy controls.

Expression of MHC class I was found in 11% of the biopsies from patients with muscular dystrophy and in 4% of those with a miscellaneous neuromuscular disorder.

Of the 13 false negative IIM patients, eight had been on chronic immunosuppressive treatment (for more than four weeks) before muscle biopsy (table 1). The remaining five false negative patients had no clinical or histological feature that distinguished them from the other IIM patients. All the IIM patients who were on short term immunosuppressive treatment (less than four weeks) before muscle biopsy (n = 6) had positive MHC class I staining (table 1).

Most of the false positive patients (n = 7) had a muscular dystrophy (three of Duchenne type; two with limb girdle dystrophy; one with oculopharyngeal dystrophy). None of these patients had clinical or histological features that distinguished them from the other patients with muscular dystrophy. The one patient from the miscellaneous disorders group with a positive MHC class I stain was a young woman with minimal symmetrical proximal muscle weakness, slightly raised creatine kinase, and a normal muscle biopsy, who did not meet the diagnostic criteria for any neuromuscular disorder.

The sensitivity for the detection of MHC class I expression on the sarcolemma for a diagnosis of IIM was 78% (95% CI, 66% to 88%), with a specificity of 95% (91% to 98%). The sensitivity before starting immunosuppressive treatment was 89% (76% to 96%). The sensitivity was unchanged by the inclusion of all patients who had been on immunosuppressive treatment for less than four weeks before muscle biopsy (sensitivity 90% (79% to 97%)).

In six patients, all fulfilling the established diagnostic criteria for IIM, no inflammatory infiltrates were found on muscle biopsy. In all six, the biopsy stained positive for MHC class I.

DISCUSSION

Histological confirmation, especially the identification of mononuclear cellular infiltrates, remains the cornerstone of the diagnosis idiopathic inflammatory myopathies. However, this typical histological characteristic can be absent in the presence of disease. MHC class I expression on the sarcolemma is upregulated in IIM and probably plays a key role in the pathogenesis of these diseases. The immunohistological detection of MHC class I antigens on the sarcolemma might serve as a diagnostic test for the diagnosis IIM. Another potential benefit of using the MHC class I staining of the sarcolemma as a diagnostic tool is that the MHC class I antigens are still detectable after immunosuppressive treatment has been initiated and in patients with chronic myositis, unlike the inflammatory infiltrates.

The main findings of this study are the high sensitivity (90%) and specificity (95%) of MHC class I staining for the diagnosis of IIM when applied to patients who had not received immunosuppressive treatment for longer than four weeks before muscle biopsy. The main reason for a false negative test result was chronic (months to years) immunosuppressive treatment before biopsy. A short (days to weeks) duration of immunosuppressive treatment before biopsy was not associated with false negative test results, thus confirming the observations by Nyberg et al. False positive test results were rarely found in Duchenne and limb girdle dystrophies.

It is of interest that six patients, in whom the diagnosis IIM was based on typical clinical characteristics and histological hallmarks other than the presence of inflammatory infiltrates, showed positive MHC class I staining without mono- nuclear cellular infiltrates in the muscle biopsy. This can be
explained by the fact that MHC class I staining is diffuse throughout the entire biopsy and is thus not affected by potential sampling errors.  

The three previous studies on MHC class I staining and IIM produced conflicting results, partly because of major differences in methodology. In the first place, Karpati et al used the PHM4 antibody for their staining technique while Appleyard et al and McDouall et al used the W6/32 antibody, as we did in this study. Second, in the studies by Karpati and Appleyard, the authors did not describe their method of assessing the stain. Third, Appleyard et al only assessed three patients with IIM, while McDouall et al only assessed five

**Table 1** Results of MHC class I staining in relation to the diagnosis of idiopathic inflammatory myopathies and the influence of the immunosuppressive treatment before muscle biopsy

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>No IS</th>
<th>IS &lt; 4 weeks (short term)</th>
<th>IS &gt; 4 weeks (chronic)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>MHC+</td>
<td>MHC−</td>
<td>MHC+</td>
</tr>
<tr>
<td>DM (n = 9)</td>
<td>5</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>PM (n = 23)</td>
<td>12</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>IBM (n = 28)</td>
<td>24</td>
<td>0</td>
<td>3</td>
</tr>
<tr>
<td>Total (n = 60)</td>
<td>41</td>
<td>5</td>
<td>6</td>
</tr>
</tbody>
</table>

Use of immunosuppressive treatment before muscle biopsy indicated by: No IS, none; IS < 4 weeks, short term; IS > 4 weeks, chronic. Values are absolute numbers.

DM, dermatomyositis; IBM, inclusion body myositis; IS, immunosuppressive treatment; PM, polymyositis; MHC+−, negative MHC class I staining of the sarcolemma; MHC++, positive MHC class I staining of the sarcolemma.
patients with polymyositis and three with inclusion body myositis. Finally, none of the three studies mentioned whether the patients had received immunosuppressive treatment before muscle biopsy.

Conclusions

Our study shows that the detection of sarcolemmal MHC class I is a valid test for IIM and that it is not affected by the short term use of immunosuppressive agents. It should be incorporated in the histological evaluation when the diagnosis of IIM is under consideration or needs to be excluded.

Authors’ affiliations

J van der Pas, G J D Hengstman, H J ter Laak, B G M van Engelen, Neuromuscular Centre, Institute of Neurology, University Medical Centre, Nijmegen, Netherlands

G F Borm, Department of Statistics, University of Nijmegen

Competing interests: none declared

REFERENCES


Diagnostic value of MHC class I staining in idiopathic inflammatory myopathies

J van der Pas, G J D Hengstman, H J ter Laak, G F Borm and B G M van Engelen

J Neurol Neurosurg Psychiatry 2004 75: 136-139

Updated information and services can be found at:
http://jnnp.bmj.com/content/75/1/136

These include:

References
This article cites 7 articles, 1 of which you can access for free at:
http://jnnp.bmj.com/content/75/1/136#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Muscle disease (257)
- Musculoskeletal syndromes (537)
- Neuromuscular disease (1311)
- Drugs: CNS (not psychiatric) (1945)
- Connective tissue disease (81)
- Drugs: musculoskeletal and joint diseases (259)
- Radiology (1747)
- Surgical diagnostic tests (401)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/